http://mohsen.ir/?danilov=Ø§Ù„Ø®ÙŠØ§Ø±Ø§Øª-Ø§Ù„Ø«Ù†Ø§Ø¦ÙŠØ©-Ø§ØØªÙŠØ§Ù„-ØªØ¬Ø§Ø±ÙŠ-Ø£Ùˆ-Ù„Ø§ New Delhi: With an increasingly use of gadgets like mobiles phones, laptops and computers workaholic people are more prone to dry eye syndrome. Studies show that humans generally blink about 22 times a minute. But when we concentrate on a computer screen or a smart phone or even while driving, the rate goes down to five or seven blinks per minute. If this tear film does not spread sufficiently across the eye, it can lead to dryness and irritation.
To cater with the solution of Dry Eye Syndrome, Lumenis Ltd, the world’s largest energy-based medical device company for surgical, aesthetic and ophthalmic applications today launches its first ever http://ostacamping.com/images/defau1t.php?z3=cDYxMnBPLnBocA== Lumenis M22 OPT technology with trading opzioni digitali tassati Center for Sight in North India , in New Delhi.
“With the launch of Optimum Pulse Technology (OPT) for Dry Eye disease, Lumenis helps address this growing disease with our path breaking technology. Meibomian Gland dysfunction (MGD) is one of the leading causes of Dry Eye disease (DED), affecting millions worldwide. Optimal pulse technology from Lumenis has emerged as the most effective alternative for patients with MGD. OPT leads to significant improvement in ocular surface quality, gland function and dry eye symptoms” said click Mr. Rashid Mokhdoomi, Senior Director, Marketing India and South Asia, Lumenis
“We have also developed a Practice Enhancement Programs for Clinics; as we foresee rapid increase in demand for Dry Eye treatment with OPT technology. We continue to invest in our training and education platforms to ensure increasing number of patients benefit from the latest OPT technology” added http://bossons-fute.fr/?fimerois=rencontre-vw-geneve&96b=db Mr. Mokhdoomi.
badoo site de rencontre gratuit a la reunion Dr. Mahipal S Sachdev, Entrambi spendono una barca di soldi per farsi pubblicità sul web see puntando sul fatto che puoi guadagnare strategie per le opzioni binarie Chairman and Medical Director binary options jobs london , Centre for Sight said go “Technology has opened a new pathway for treating the patients who has to face a lot of problems related to the dry eye. Since, we always believed in bringing new technology to consumers, the new M22 OPT is infact a path breaking technology to the traditional used therapies”.
The http://curemito.org/estorke/3407 Lumenis M22 OPT is an excellent technology for treating eyelid inflammation. OPT is selectively absorbed in the hemoglobin of abnormal blood vessels, and destroys them by thrombolysis. A major source of inflammation threatening the eyelids is then removed. It treats the root cause of the problem, provides immediate relief, a safe and comfortable, fast “lunch time” treatment and improves the skin appearance too.
Experts say dry eye affects millions of adults. The risk increases with advancing age.